Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Editors’ Picks for 2014 and a Look into the Future

Editors’ Picks for 2014 and a Look into the Future Cardiol Ther (2015) 4:1–3 DOI 10.1007/s40119-015-0038-y EDITORIAL • • Robert P. Giugliano Uwe Zeymer Ian Menown To view enhanced content go to www.cardiologytherapy-open.com Received: January 27, 2015 / Published online: March 13, 2015 The Author(s) 2015. This article is published with open access at Springerlink.com Keywords: PCSK9 inhibitor; Low-density In the field of lipids, several studies with lipoprotein cholesterol; Ezetimibe; Statin proprotein convertase subtilisin kexin 9 therapy; Angiotensin receptor blocker; (PCSK9) inhibitors demonstrated their potent LCZ696; Valsartan/sacubitril; Enalapril; effects to lower low-density-lipoprotein Transcatheter aortic valve implantation; cholesterol (LDL-C) in a wide variety of Antiplatelet therapy patients. In addition to reducing LDL-C by 50% or more, PCSK9 inhibitors have favorable effects on apolipoprotein-B, lipoprotein (a), and The year 2014 brought a large number of triglycerides. Although much less potent than important advances to cardiovascular medicine the PCSK9 inhibitors, the cholesterol that are likely to impact the field for many absorption inhibitor ezetimibe became the first years, if not decades [1]. Herein are our non-statin to demonstrate a reduction in thoughts on the top stories in 2014 and what cardiovascular events on top of background is likely to remain hot in 2015. statin therapy. In the IMPROVE IT trial (ClinicalTrials.gov NCT http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cardiology and Therapy Springer Journals

Editors’ Picks for 2014 and a Look into the Future

Download PDF
3 pages

Loading next page...
 
/lp/springer-journals/editors-picks-for-2014-and-a-look-into-the-future-XYtfhA02G0
Publisher
Springer Journals
Copyright
Copyright © 2015 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine; Cardiology
ISSN
2193-8261
eISSN
2193-6544
DOI
10.1007/s40119-015-0038-y
pmid
25766962
Publisher site
See Article on Publisher Site

Abstract

Cardiol Ther (2015) 4:1–3 DOI 10.1007/s40119-015-0038-y EDITORIAL • • Robert P. Giugliano Uwe Zeymer Ian Menown To view enhanced content go to www.cardiologytherapy-open.com Received: January 27, 2015 / Published online: March 13, 2015 The Author(s) 2015. This article is published with open access at Springerlink.com Keywords: PCSK9 inhibitor; Low-density In the field of lipids, several studies with lipoprotein cholesterol; Ezetimibe; Statin proprotein convertase subtilisin kexin 9 therapy; Angiotensin receptor blocker; (PCSK9) inhibitors demonstrated their potent LCZ696; Valsartan/sacubitril; Enalapril; effects to lower low-density-lipoprotein Transcatheter aortic valve implantation; cholesterol (LDL-C) in a wide variety of Antiplatelet therapy patients. In addition to reducing LDL-C by 50% or more, PCSK9 inhibitors have favorable effects on apolipoprotein-B, lipoprotein (a), and The year 2014 brought a large number of triglycerides. Although much less potent than important advances to cardiovascular medicine the PCSK9 inhibitors, the cholesterol that are likely to impact the field for many absorption inhibitor ezetimibe became the first years, if not decades [1]. Herein are our non-statin to demonstrate a reduction in thoughts on the top stories in 2014 and what cardiovascular events on top of background is likely to remain hot in 2015. statin therapy. In the IMPROVE IT trial (ClinicalTrials.gov NCT

Journal

Cardiology and Therapy – Springer Journals

Published: Mar 13, 2015

References

  • Key clinical trials of 2014
    McKavanagh, P; McCune, C; Menown, IB